Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model.

This research investigates potential vaccines for the horse pathogen Rhodococcus equi, which causes a type of pneumonia in foals, based on the pathogen’s VapA protein. While both a DNA and a protein vaccine elicit the desired immune response in mice, neither provided protection when the mice were exposed to.

Background

• The study sought to develop potential vaccines to counteract Rhodococcus equi, a pathogen that causes pyogranulomatous bronchopneumonia, a severe lung infection in foals.
• This pathogen is a significant problem in the equine industry and despite several efforts, no commercial vaccines are currently available to prevent this disease.
• Prior research indicates that a Th1 immune response, a type of immune system reaction, is crucial for protection against R. equi disease.

Vaccines Based on VapA Protein

• The researchers developed two kinds of experimental vaccines centered on VapA, a protein associated with R. equi virulence.
• The vaccines were a DNA vaccine and a recombinant protein vaccine, both designed to elicit the desired Th1 immune response.

Testing and Results

• The vaccines were tested on the BALB/c mouse model, a common laboratory mouse strain used in scientific research.
• The results indicated that both experimental vaccines succeed in eliciting a Th1-type immune response.
• When researchers supplemented the DNA vaccine with an IL-12 expression plasmid, they observed an increased Th1 response.

Efficacy and Protection

• However, when these vaccinated mice were exposed to a high dose of the virulent strain of R. equi, none exhibited protection, except for the group that received a live R. equi vaccine.
• This implies that while these experimental vaccines stimulated the desired immune response, they were not effective in preventing bacterial replication after exposure to a high-dose, suggesting they may not be effective in preventing the disease.

Conclusion

• The VapA-based DNA and recombinant protein vaccines, while provoking a proper immune response, failed to provide adequate protection in the mouse model.
• The findings in this study underscore the challenges in developing an effective vaccine against R. equi and the need for further research.